{"id":"neuraceq-florbetaben-18f","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Florbetaben is a fluorine-18 labeled benzofuran derivative that crosses the blood-brain barrier and selectively binds to amyloid-beta aggregates in the brain. The radioactive fluorine-18 isotope enables PET imaging to visualize and quantify amyloid burden, allowing clinicians to assess amyloid pathology in patients with cognitive impairment or suspected Alzheimer's disease.","oneSentence":"Florbetaben 18F is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:03.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Detection of amyloid pathology in patients with cognitive impairment suspected to be due to Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05617014","phase":"","title":"Alzheimer's Disease Neuroimaging Initiative 4","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2023-06-09","conditions":"Mild Cognitive Impairment, Alzheimer Disease, Dementia","enrollment":1500},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":"Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment","enrollment":850},{"nctId":"NCT06932809","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-05-09","conditions":"Tauopathies","enrollment":90},{"nctId":"NCT06790394","phase":"PHASE1","title":"Test-retest Study With [18F]FBB in Cardiac Amyloidosis","status":"RECRUITING","sponsor":"Life Molecular Imaging GmbH","startDate":"2025-10-21","conditions":"Cardiac Amyloidosis","enrollment":15},{"nctId":"NCT05184088","phase":"PHASE3","title":"Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis","status":"RECRUITING","sponsor":"Life Molecular Imaging GmbH","startDate":"2023-01-13","conditions":"Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis","enrollment":200},{"nctId":"NCT06032026","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-20","conditions":"Tauopathies","enrollment":70},{"nctId":"NCT06303921","phase":"EARLY_PHASE1","title":"Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-02-16","conditions":"Tauopathies","enrollment":70},{"nctId":"NCT02831283","phase":"PHASE2","title":"Imaging Inflammation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Patrick Lao","startDate":"2016-06","conditions":"Alzheimer's Disease","enrollment":60},{"nctId":"NCT03616496","phase":"NA","title":"Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2019-06-06","conditions":"Cardiac Amyloidosis","enrollment":67},{"nctId":"NCT04105634","phase":"EARLY_PHASE1","title":"Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-10-01","conditions":"Cardiac Amyloidosis","enrollment":3},{"nctId":"NCT04720001","phase":"","title":"Florbetaben PET Imaging in PPA","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-08-23","conditions":"Primary Progressive Aphasia, Alzheimer Disease","enrollment":1},{"nctId":"NCT05270083","phase":"NA","title":"Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2017-07-13","conditions":"Concussion, Brain","enrollment":15},{"nctId":"NCT03075007","phase":"","title":"Brain Vascular Disease in Aging and Dementia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-05-23","conditions":"Alzheimer Disease, White Matter Hyperintensities, Dementia","enrollment":48},{"nctId":"NCT03119558","phase":"EARLY_PHASE1","title":"PET/MRI Evaluation of Cardiac Amyloid","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-05-26","conditions":"Cardiac Amyloidosis","enrollment":9},{"nctId":"NCT03779815","phase":"NA","title":"Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography","status":"COMPLETED","sponsor":"Ulsan University Hospital","startDate":"2018-08-20","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT02681172","phase":"PHASE4","title":"Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD","status":"COMPLETED","sponsor":"Piramal Imaging Limited","startDate":"2015-10","conditions":"Alzheimer's Disease (AD)","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FBB"],"phase":"marketed","status":"active","brandName":"Neuraceq (florbetaben 18F)","genericName":"Neuraceq (florbetaben 18F)","companyName":"Piramal Imaging Limited","companyId":"piramal-imaging-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Florbetaben 18F is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology. Used for Detection of cerebral amyloid-beta in patients with cognitive impairment or suspected Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}